207 related articles for article (PubMed ID: 37805590)
1. Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity.
Broeker CD; Ortiz MMO; Murillo MS; Andrechek ER
Breast Cancer Res; 2023 Oct; 25(1):120. PubMed ID: 37805590
[TBL] [Abstract][Full Text] [Related]
2. A mouse model with T58A mutations in Myc reduces the dependence on KRas mutations and has similarities to claudin-low human breast cancer.
Hollern DP; Yuwanita I; Andrechek ER
Oncogene; 2013 Mar; 32(10):1296-304. PubMed ID: 22525269
[TBL] [Abstract][Full Text] [Related]
3. Genetic heterogeneity of Myc-induced mammary tumors reflecting diverse phenotypes including metastatic potential.
Andrechek ER; Cardiff RD; Chang JT; Gatza ML; Acharya CR; Potti A; Nevins JR
Proc Natl Acad Sci U S A; 2009 Sep; 106(38):16387-92. PubMed ID: 19805309
[TBL] [Abstract][Full Text] [Related]
4. Histological subtypes of mouse mammary tumors reveal conserved relationships to human cancers.
Hollern DP; Swiatnicki MR; Andrechek ER
PLoS Genet; 2018 Jan; 14(1):e1007135. PubMed ID: 29346386
[TBL] [Abstract][Full Text] [Related]
5. The epigenetic modifier JMJD6 is amplified in mammary tumors and cooperates with c-Myc to enhance cellular transformation, tumor progression, and metastasis.
Aprelikova O; Chen K; El Touny LH; Brignatz-Guittard C; Han J; Qiu T; Yang HH; Lee MP; Zhu M; Green JE
Clin Epigenetics; 2016; 8():38. PubMed ID: 27081402
[TBL] [Abstract][Full Text] [Related]
6. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
7. Metabolomic profiling of mouse mammary tumor-derived cell lines reveals targeted therapy options for cancer subtypes.
Ogrodzinski MP; Teoh ST; Lunt SY
Cell Oncol (Dordr); 2020 Dec; 43(6):1117-1127. PubMed ID: 32691367
[TBL] [Abstract][Full Text] [Related]
8. Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer.
Tanioka M; Mott KR; Hollern DP; Fan C; Darr DB; Perou CM
Genome Med; 2018 Nov; 10(1):86. PubMed ID: 30497520
[TBL] [Abstract][Full Text] [Related]
9. Clinical and molecular relevance of mutant-allele tumor heterogeneity in breast cancer.
Ma D; Jiang YZ; Liu XY; Liu YR; Shao ZM
Breast Cancer Res Treat; 2017 Feb; 162(1):39-48. PubMed ID: 28093659
[TBL] [Abstract][Full Text] [Related]
10. Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis.
Bosch A; Bertran SP; Lu Y; Garcia A; Jones AM; Dawson MI; Farias EF
Breast Cancer Res; 2012 Aug; 14(4):R121. PubMed ID: 22920668
[TBL] [Abstract][Full Text] [Related]
11. MMTV-LIKE virus and c-myc over-expression are associated with invasive breast cancer.
Khalid HF; Ali A; Fawad N; Rafique S; Ullah I; Rehman G; Shams MU; Idrees M
Infect Genet Evol; 2021 Jul; 91():104827. PubMed ID: 33794352
[TBL] [Abstract][Full Text] [Related]
12. Frequent overexpression of AMAP1, an Arf6 effector in cell invasion, is characteristic of the MMTV-PyMT rather than the MMTV-Neu human breast cancer model.
Otsuka Y; Oikawa T; Yoshino H; Hashimoto S; Handa H; Yamamoto H; Hashimoto A; Sabe H
Cell Commun Signal; 2018 Jan; 16(1):1. PubMed ID: 29329590
[TBL] [Abstract][Full Text] [Related]
13. Potential mouse tumor model for pre-clinical testing of mage-specific breast cancer vaccines.
Sypniewska RK; Hoflack L; Bearss DJ; Gravekamp C
Breast Cancer Res Treat; 2002 Jun; 74(3):221-33. PubMed ID: 12211215
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneity in MYC-induced mammary tumors contributes to escape from oncogene dependence.
Leung JY; Andrechek ER; Cardiff RD; Nevins JR
Oncogene; 2012 May; 31(20):2545-54. PubMed ID: 21996730
[TBL] [Abstract][Full Text] [Related]
15. An integration of complementary strategies for gene-expression analysis to reveal novel therapeutic opportunities for breast cancer.
Bild AH; Parker JS; Gustafson AM; Acharya CR; Hoadley KA; Anders C; Marcom PK; Carey LA; Potti A; Nevins JR; Perou CM
Breast Cancer Res; 2009; 11(4):R55. PubMed ID: 19638211
[TBL] [Abstract][Full Text] [Related]
16. Molecular Characterization and Landscape of Breast cancer Models from a multi-omics Perspective.
Ortiz MMO; Andrechek ER
J Mammary Gland Biol Neoplasia; 2023 Jun; 28(1):12. PubMed ID: 37269418
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic CRBP downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer.
Arapshian A; Bertran S; Kuppumbatti YS; Nakajo S; Mira-y-Lopez R
Mol Cancer; 2004 Apr; 3():13. PubMed ID: 15113415
[TBL] [Abstract][Full Text] [Related]
18. Prognostic and predictive significance of MYC and KRAS alterations in breast cancer from women treated with neoadjuvant chemotherapy.
Pereira CB; Leal MF; de Souza CR; Montenegro RC; Rey JA; Carvalho AA; Assumpção PP; Khayat AS; Pinto GR; Demachki S; de Arruda Cardoso Smith M; Burbano RR
PLoS One; 2013; 8(3):e60576. PubMed ID: 23555992
[TBL] [Abstract][Full Text] [Related]
19. Deletion of the murine ortholog of the 8q24 gene desert has anti-cancer effects in transgenic mammary cancer models.
Homer-Bouthiette C; Zhao Y; Shunkwiler LB; Van Peel B; Garrett-Mayer E; Baird RC; Rissman AI; Guest ST; Ethier SP; John MC; Powers PA; Haag JD; Gould MN; Smits BMG
BMC Cancer; 2018 Dec; 18(1):1233. PubMed ID: 30526553
[TBL] [Abstract][Full Text] [Related]
20. Effective personalized therapy for breast cancer based on predictions of cell signaling pathway activation from gene expression analysis.
Jhan JR; Andrechek ER
Oncogene; 2017 Jun; 36(25):3553-3561. PubMed ID: 28135251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
